PolyPid Ltd. is a biopharmaceutical company developing novel drug delivery solutions for infectious diseases, with its lead product D-PLEX100—a localized, extended-release antibiotic formulation designed to prevent surgical site infections—utilizing the company's proprietary PLEX polymer-based delivery platform. The company is advancing D-PLEX100 through clinical development for regulatory approval with the FDA, having received fast-track, breakthrough therapy, and QIDP designations; it plans to commercialize the product through partnerships with third-party distributors or internal sales infrastructure rather than direct manufacturing and marketing. PolyPid has generated no product revenue to date and remains unprofitable, financing operations through equity offerings and research grants while focusing development efforts on obtaining regulatory approval and achieving physician and hospital adoption.